R 348

Drug Profile

R 348

Alternative Names: R 932348; R348

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antirheumatics; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Keratoconjunctivitis sicca; Psoriasis; Rheumatoid arthritis; Skin disorders; Transplant rejection

Most Recent Events

  • 27 Feb 2017 Discontinued - Phase-II for Graft-versus-host disease in USA (Ophthalmic)
  • 01 Jul 2016 Rigel Pharmaceuticals completes the phase II DROPS-2 trial for Keratoconjunctivitis sicca in patients with ocular Graft-versus-host disease in USA (NCT02040623)
  • 13 Aug 2014 Discontinued - Phase-II for Keratoconjunctivitis sicca in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top